There is no single “best” HIV medication for everyone, but two regimens consistently top the list. U.S. treatment guidelines give their strongest recommendation to regimens built around bictegravir or dolutegravir, both belonging to a class of drugs called integrase inhibitors. These medications block HIV from inserting its genetic code into your cells, and they work so well that most people who take them reach an undetectable viral load within months and stay there for years.
Which specific combination your provider recommends depends on your viral load, other health conditions, medications you already take, and personal preferences. Here’s what you need to know about the options.
The Two Most Recommended Regimens
Current U.S. guidelines from the National Institutes of Health recommend three first-line options for most people starting treatment for the first time. All carry the highest possible evidence rating, meaning they’re backed by data from randomized controlled trials and strong expert consensus.
- Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide): A single pill taken once daily that contains a complete three-drug regimen. It’s the most widely prescribed HIV medication in the U.S.
- Dolutegravir plus two backbone drugs: Dolutegravir paired with either tenofovir alafenamide or tenofovir disoproxil fumarate, plus emtricitabine or lamivudine. This combination may involve one or two pills daily depending on the formulation.
- Dovato (dolutegravir/lamivudine): A two-drug, single-pill regimen. It’s a good option for many people but isn’t recommended if your viral load is above 500,000 copies/mL, if you have hepatitis B, or if treatment needs to start before resistance test results come back.
In a head-to-head trial comparing Biktarvy and Dovato, both achieved excellent results at 96 weeks. About 90% of people on Dovato and 86% on Biktarvy had fully suppressed viral loads below 50 copies/mL. The difference was small enough that both are considered equally effective for eligible patients.
Why Integrase Inhibitors Dominate
HIV drugs fall into eight classes, each targeting a different step in the virus’s life cycle. Integrase inhibitors are preferred as the foundation of treatment because they suppress the virus faster, cause fewer drug interactions than older classes, and are generally well tolerated. Older drug classes like protease inhibitors and non-nucleoside reverse transcriptase inhibitors are still used in specific situations, such as when resistance testing shows the virus won’t respond to integrase inhibitors, but they’re no longer first-line for most people.
Protease inhibitors, for example, interact with a long list of common medications including blood thinners, cholesterol drugs, seizure medications, and even some antifungals. Integrase inhibitors have a much simpler interaction profile, though they do have one important quirk: supplements and antacids containing calcium, magnesium, aluminum, iron, or zinc can bind to integrase inhibitors in your stomach and reduce how much drug your body absorbs. Spacing these supplements a few hours from your HIV medication solves the problem.
Weight Gain and Metabolic Effects
The most discussed side effect of modern HIV treatment is weight gain. It’s most pronounced with bictegravir, dolutegravir, and tenofovir alafenamide, the exact drugs in today’s preferred regimens. Pooled data from eight clinical trials found that roughly 13% of people starting treatment gain more than 10% of their body weight within the first year.
Certain groups tend to experience more weight gain: women, older adults, Black individuals, and people who had more advanced HIV at the time they started treatment. People who switch to an integrase inhibitor from an older regimen while already virally suppressed also appear more susceptible. In follow-up studies, those who gained more than 10% of their body weight in the first year had a higher risk of developing type 2 diabetes and metabolic syndrome.
That said, treatment guidelines are clear that weight gain concerns should not be the reason to avoid these regimens. The benefits of reliable viral suppression far outweigh the metabolic risks, and the reasons behind the weight changes aren’t fully understood. Some of the gain likely reflects a return to healthier weight after the immune system recovers.
Bone and Kidney Considerations
Two versions of tenofovir are used in HIV treatment. The newer form, tenofovir alafenamide (TAF), delivers the drug more efficiently to cells, resulting in lower levels circulating in the blood. The older form, tenofovir disoproxil fumarate (TDF), produces higher blood levels, which can affect the kidneys and bones over time.
When either version is combined with a boosting agent (a drug that increases blood levels of the primary medication), the difference matters more. In that scenario, the older formulation is linked to more bone fractures, greater bone density loss, and more treatment discontinuations due to kidney problems. Without a booster, the safety differences between the two versions are marginal.
Since the most commonly prescribed first-line regimens (like Biktarvy) don’t use a booster with tenofovir, this distinction is less critical for most people starting treatment today. But if you have pre-existing kidney disease or osteoporosis, your provider will factor this into the decision.
Injectable Treatment: An Alternative to Daily Pills
For people who are already virally suppressed and want to stop taking daily pills, an injectable option called Cabenuva is available. It combines two drugs, cabotegravir and rilpivirine, given as injections either once a month or once every two months.
Cabenuva isn’t a starting regimen. You’re eligible only if you’ve been on a stable oral regimen, your viral load is already undetectable (below 50 copies/mL), and you have no history of treatment failure or suspected resistance to the drugs in the injection. The injections are given by a healthcare provider at a clinic, so the tradeoff is swapping daily pills for regular office visits.
How Your Regimen Gets Chosen
Before you start any HIV medication, your provider will order a resistance test. This is a genetic analysis of the virus in your blood that identifies mutations affecting which drugs will work. The standard approach is genotypic testing, which reads the genetic sequence of the virus and looks for known resistance patterns. It typically requires a viral load of at least 500 to 1,000 copies/mL to work.
For most people diagnosed today, the virus will be fully susceptible to integrase inhibitors, and one of the three preferred regimens will be the right fit. If there’s any chance you were previously exposed to cabotegravir as a prevention drug (PrEP), your provider will specifically test for integrase inhibitor resistance before choosing a regimen. In that case, a protease inhibitor-based regimen may be used temporarily until results come back.
Beyond resistance, the decision involves practical factors: how many pills you’re comfortable taking, other medications you use, whether you have hepatitis B (which affects drug choice), kidney function, bone health, pregnancy plans, and your preferences around potential side effects like weight changes. Two people with the same resistance profile might reasonably end up on different regimens based on these individual factors.
Newer Drugs on the Horizon
Lenacapavir, a capsid inhibitor that works by a completely different mechanism than older drug classes, was approved by the FDA in June 2025 for HIV prevention. It’s given as an injection just once every six months. In two large trials, it reduced the risk of acquiring HIV by 96% to 100% over a year of follow-up. Lenacapavir was already approved for treatment in people with drug-resistant HIV, and its role in broader treatment regimens is expanding. A twice-yearly injection for both prevention and treatment could significantly change how HIV is managed in the coming years.